Monocentric, exploratory study comparing 68Ga-RM2 PET / CT to 68Ga-PSMA-617 PET / CT in prostate cancer patients with different metastatic risks, candidates for total prostatectomy (Etude monocentrique, exploratoire, comparant la TEP/TDM au 68Ga-RM2 à la TEP/TDM au 68Ga-PSMA-617 chez des patients atteints de cancers de la prostate de différents risques métastatiques, candidats à une prostatectomie totale}

Trial Profile

Monocentric, exploratory study comparing 68Ga-RM2 PET / CT to 68Ga-PSMA-617 PET / CT in prostate cancer patients with different metastatic risks, candidates for total prostatectomy (Etude monocentrique, exploratoire, comparant la TEP/TDM au 68Ga-RM2 à la TEP/TDM au 68Ga-PSMA-617 chez des patients atteints de cancers de la prostate de différents risques métastatiques, candidats à une prostatectomie totale}

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs 68-Ga-PSMA-617 (Primary) ; Gallium 68 RM2 (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Acronyms UROPET
  • Most Recent Events

    • 01 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top